Example triggers

Novo Nordisk has a dense pipeline of catalysts through early 2027 that could materially shift investor perception of its growth trajectory and competitive position. The most commercially significant near-term events are the UK and EU launches of Wegovy® in pill form (expected September–October 2026), which would expand access to the company's blockbuster weight-loss treatment beyond injection-dependent patients and directly compete with Eli Lilly's oral offering. Alongside these, the full results from the ZEUS phase 3 trial (expected November 2026) could establish semaglutide—Novo's flagship GLP-1 drug—as a treatment for cardiovascular and kidney disease beyond diabetes, substantially widening its addressable market, while a separate readout on semaglutide for liver disease (expected January 2027) represents another potential indication expansion. On the legal and strategic side, the outcome of Eli Lilly's misleading advertising lawsuit and any updates on the AWS partnership for AI-driven drug discovery by February 2027 will be watched as signals of competitive vulnerability and future innovation capability respectively. The full-year 2026 financial results (February 2027) and the Annual General Meeting in March 2027 will then provide the board and management's first comprehensive reflection on execution against these milestones.

• Resolution or further update on IT security incident at Novo NordiskSpeculativeSep 1, 2026
• Wegovy® pill commercial launch in the UK following MHRA approvalMedium confidenceSep 15, 2026
• Wegovy® pill commercial launch in first EU markets following EC approvalMedium confidenceOct 15, 2026
• ZEUS phase 3 trial full results presentation or regulatory filing update (ASCVD/CKD/inflammation)Medium confidenceNov 15, 2026
• Eli Lilly vs. Novo Nordisk misleading GLP-1 advertising litigation outcome or settlementSpeculativeDec 15, 2026
• Semaglutide liver disease (MASLD/MASH) regulatory filing or pivotal trial readoutMedium confidenceJan 15, 2027
• Novo Nordisk full-year 2026 annual results publicationHigh confidenceFeb 4, 2027
• First deliverables or milestone update from Novo Nordisk–AWS AI drug discovery partnershipSpeculativeFeb 15, 2027
• Novo Nordisk Annual General Meeting 2027High confidenceMar 26, 2027
• NOVO B ex-dividend date for H2 2026 interim dividendHigh confidenceMar 28, 2027

Tesla has six significant corporate milestones tracked over the next fifteen months, with delivery results and earnings reports in October 2026 likely to be the most market-moving events given their direct bearing on financial performance. Between the Cybercab's broader commercial launch, regulatory decisions on autonomous driving technology in China, and the speculative Tesla-SpaceX merger discussions, investor attention will focus on whether Tesla can demonstrate progress on next-generation vehicles and international regulatory approvals that could unlock new revenue streams. The recall remediation update in China carries particular importance given the region's contribution to Tesla's overall sales and the regulatory scrutiny autonomous and safety-critical systems face there.

• Cybercab public rollout beyond employee rides in AustinMedium confidenceSep 15, 2026
• Tesla Q3 2026 delivery results expectedHigh confidenceOct 2, 2026
• China recall remediation completion or regulatory update expectedMedium confidenceOct 15, 2026
• Tesla Q3 2026 earnings report expectedHigh confidenceOct 22, 2026
• Further Tesla-SpaceX merger developments or formal proposal expectedSpeculativeOct 31, 2026
• Tesla China FSD regulatory approval decision or progress updateMedium confidenceNov 15, 2026

Boliden faces a critical recovery window through mid-2026 as its flagship Garpenberg zinc-copper mine gradually restarts following a partial collapse, with production expected to reach only 30% of normal levels in Q2 before climbing toward 50% by autumn. The market is watching for three key milestones: management's updated recovery roadmap (expected May), Q2 earnings showing the financial impact of severely reduced output (late July), and the results of a safety investigation into the collapse that could reshape operational protocols across all Boliden mines (mid-June). Meanwhile, the company's exploration partnerships in Canada and a potentially game-changing water-treatment technology pilot at its Rönnskär smelter offer longer-term upside, though near-term investor sentiment will likely hinge on whether Garpenberg's recovery stays on track and how much production Boliden can realistically recapture in 2026.

• Garpenberg production resumes at ~30% of guided capacity (Q2 partial restart per company guidance)High confidenceApr 15, 2026
• Boliden expected to present updated Garpenberg mine plan / production recovery roadmap (analysts waiting before re-rating)Medium confidenceMay 15, 2026
• Amarc Resources 2026 exploration program at Duke Copper-Gold District (Boliden partner) set to commence in JuneHigh confidenceJun 1, 2026
• Boliden-funded 2026 drill program at Rayfield Copper-Gold Project expected to commence (summer field season)Medium confidenceJun 15, 2026
• Kristineberg mine collapse investigation results expected — could affect safety protocols across Boliden minesMedium confidenceJun 15, 2026
• Monitoring whether Capital Fund Management increases or exits short position in Boliden (short interest may rise given Garpenberg aftershocks)SpeculativeJun 30, 2026
• Boliden Mineral Canada expected to begin exploration expenditures at Thompson East under staged earn-in (first phase field work)Medium confidenceJul 15, 2026
• Boliden Q2 2026 earnings report expected (with severely reduced Garpenberg production — only 0.1Mt guided for Q2)High confidenceJul 28, 2026
• Odda zinc smelter expansion ramp-up progress update expected with Q2 resultsHigh confidenceJul 28, 2026
• Boliden expected to appoint new Communications Director to replace Klas Nilsson (departing to SCA in autumn 2026)Medium confidenceAug 15, 2026
• Garpenberg production expected to reach ~50% recovery (SB1 Markets estimates 50% lost annual production in 2026)Medium confidenceSep 15, 2026
• Långdahls hopes to rehire workers once Garpenberg returns to normal production — rehiring contingent on production recovery timelineSpeculativeOct 15, 2026
• Boliden strategic projects / expansions net lower impact expected in 2027 (analyst projection)Medium confidenceFeb 15, 2027